A subsidiary of Akzo Nobel of the Netherlands, Pharmaceutical Basics Inc of the USA - which has been renamed Rosemont Pharmaceutical Corporation - has said that arbitration in which it has been involved was not conducted with due process.
International arbitration found that PBI had breached a 1989 contract with a UK firm, Generica Ltd, that called for PBI to carry out the development and manufacture, and cooperate in the regulatory approval and marketing of generic clomiphene citrate, used in the treatment of female infertility.
The arbitration resulted in an award of $7 million to Generica. PBI was found to have failed to perform its obligations under the 1989 contract, which included failure to file an Abbreviated New Drug Application with the US Food and Drug Administration, and failure to provide Generica with the manufacturing data that was necessary for an ANDA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze